Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Market Cap	58.80B
Revenue (ttm)	14.32B
Net Income (ttm)	245.19M
Shares Out	300.00M
EPS (ttm)	0.82
PE Ratio	239.81
Forward PE	n/a
Dividend	1.11 (0.58%)
Ex-Dividend Date	Aug 12, 2025

Volume	1,875,569
Average Volume	2,638,612
Open	202.50
Previous Close	202.00
Day's Range	192.50 - 204.10
52-Week Range	75.00 - 202.00
Beta	1.06
RSI	67.02
Earnings Date	Aug 14, 2025

About Model N

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 619
• Stock Exchange: Istanbul Stock Exchange
• Ticker Symbol: GENIL

Financial Performance

In 2024, IST:GENIL's revenue was 14.74 billion, an increase of 25.25% compared to the previous year's 11.77 billion. Earnings were 148.68 million, a decrease of -77.35%.